These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

724 related articles for article (PubMed ID: 26707800)

  • 21. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
    Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
    EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BET bromodomain inhibitors--a novel epigenetic approach in castration-resistant prostate cancer.
    Lochrin SE; Price DK; Figg WD
    Cancer Biol Ther; 2014; 15(12):1583-5. PubMed ID: 25535892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemical Proteomic Profiling of Bromodomains Enables the Wide-Spectrum Evaluation of Bromodomain Inhibitors in Living Cells.
    Li X; Wu Y; Tian G; Jiang Y; Liu Z; Meng X; Bao X; Feng L; Sun H; Deng H; Li XD
    J Am Chem Soc; 2019 Jul; 141(29):11497-11505. PubMed ID: 31246451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.
    Chaidos A; Caputo V; Karadimitris A
    Ther Adv Hematol; 2015 Jun; 6(3):128-41. PubMed ID: 26137204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs.
    Borck PC; Guo LW; Plutzky J
    Circ Res; 2020 Apr; 126(9):1190-1208. PubMed ID: 32324495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.
    Baud MG; Lin-Shiao E; Zengerle M; Tallant C; Ciulli A
    J Med Chem; 2016 Feb; 59(4):1492-500. PubMed ID: 26367539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bromodomains: A novel target for the anticancer therapy.
    Gokani S; Bhatt LK
    Eur J Pharmacol; 2021 Nov; 911():174523. PubMed ID: 34563497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JQ1 affects BRD2-dependent and independent transcription regulation without disrupting H4-hyperacetylated chromatin states.
    Handoko L; Kaczkowski B; Hon CC; Lizio M; Wakamori M; Matsuda T; Ito T; Jeyamohan P; Sato Y; Sakamoto K; Yokoyama S; Kimura H; Minoda A; Umehara T
    Epigenetics; 2018; 13(4):410-431. PubMed ID: 30080437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of BET bromodomains alleviates inflammation in human RPE cells.
    Hytti M; Tokarz P; Määttä E; Piippo N; Korhonen E; Suuronen T; Honkakoski P; Kaarniranta K; Lahtela-Kakkonen M; Kauppinen A
    Biochem Pharmacol; 2016 Jun; 110-111():71-9. PubMed ID: 27106081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
    Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
    Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acetylation of CCAR2 Establishes a BET/BRD9 Acetyl Switch in Response to Combined Deacetylase and Bromodomain Inhibition.
    Rajendran P; Johnson G; Li L; Chen YS; Dashwood M; Nguyen N; Ulusan A; Ertem F; Zhang M; Li J; Sun D; Huang Y; Wang S; Leung HC; Lieberman D; Beaver L; Ho E; Bedford M; Chang K; Vilar E; Dashwood R
    Cancer Res; 2019 Mar; 79(5):918-927. PubMed ID: 30643017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Profiling the regulatory interplay of BET bromodomains and Sirtuins in cancer cell lines.
    Järvenpää J; Rahnasto-Rilla M; Lahtela-Kakkonen M; Küblbeck J
    Biomed Pharmacother; 2022 Mar; 147():112652. PubMed ID: 35065514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
    Mirguet O; Gosmini R; Toum J; Clément CA; Barnathan M; Brusq JM; Mordaunt JE; Grimes RM; Crowe M; Pineau O; Ajakane M; Daugan A; Jeffrey P; Cutler L; Haynes AC; Smithers NN; Chung CW; Bamborough P; Uings IJ; Lewis A; Witherington J; Parr N; Prinjha RK; Nicodème E
    J Med Chem; 2013 Oct; 56(19):7501-15. PubMed ID: 24015967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
    Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
    Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
    Chung CW; Coste H; White JH; Mirguet O; Wilde J; Gosmini RL; Delves C; Magny SM; Woodward R; Hughes SA; Boursier EV; Flynn H; Bouillot AM; Bamborough P; Brusq JM; Gellibert FJ; Jones EJ; Riou AM; Homes P; Martin SL; Uings IJ; Toum J; Clement CA; Boullay AB; Grimley RL; Blandel FM; Prinjha RK; Lee K; Kirilovsky J; Nicodeme E
    J Med Chem; 2011 Jun; 54(11):3827-38. PubMed ID: 21568322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.
    Morse MA; Balogh KK; Brendle SA; Campbell CA; Chen MX; Furze RC; Harada IL; Holyer ID; Kumar U; Lee K; Prinjha RK; Rüdiger M; Seal JT; Taylor S; Witherington J; Christensen ND
    Antiviral Res; 2018 Jun; 154():158-165. PubMed ID: 29653131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains.
    Fedorov O; Lingard H; Wells C; Monteiro OP; Picaud S; Keates T; Yapp C; Philpott M; Martin SJ; Felletar I; Marsden BD; Filippakopoulos P; Müller S; Knapp S; Brennan PE
    J Med Chem; 2014 Jan; 57(2):462-76. PubMed ID: 24313754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bromodomains and their pharmacological inhibitors.
    Gallenkamp D; Gelato KA; Haendler B; Weinmann H
    ChemMedChem; 2014 Mar; 9(3):438-64. PubMed ID: 24497428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.